Shorter, cheaper liver scans for cancer patients? small study tests new approach
NCT ID NCT04973007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two different contrast agents used in liver MRI scans to see if a shorter, cheaper scan could work as well as the standard one for finding colorectal cancer that has spread to the liver. The trial planned to enroll 10 adults with suspected liver metastases, but it was terminated early. The goal was to save time and money without missing cancer spots.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gadobenate dimeglumine (MultiHance) and gadoxetate disodium (Primovist/Eovist)
- What this could lead to
- If successful, this could make liver MRI scans faster, cheaper, and easier for patients while still finding cancer spread effectively.
- What could go wrong
- This was a very small, terminated study with only 10 participants, so results are limited and may not apply broadly. The approach may not be as accurate as the standard method.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
10 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Colorectal cancer patients * Age 18-80 years * No prior treatment including surgery * Prior imaging with suspected liver metastasis Exclusion Criteria: * Age \< 18 years or \> 80 years * eGFR \< 30 ml/min/1.73 m2 * Previous reaction to gadolinium contrast agents * History of claustrophobia or movement disorders likely to impact image quality * Non-MR safe implants or metallic foreign bodies
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?